



浙江华海药业股份有限公司

HUHHAI ZHEJIANG HUHHAI PHARMACEUTICAL CO.,LTD.

中国 浙江 临海 杜桥 川南  
CHUANNAN, DUQIAO, LINHAI  
ZHEJIANG 317016, CHINA.  
Tel: +86(576)85010288  
Fax: +86(576)85991062

Email: sales@huahaipharm.com  
http://www.huahaipharm.com

## CERTIFICATE OF ANALYSIS

Page 1 of 1

Page 1 of 1

| Tadalafil                     |                                                                   |                    |                                                     |
|-------------------------------|-------------------------------------------------------------------|--------------------|-----------------------------------------------------|
| Product Name                  |                                                                   |                    |                                                     |
| Batch No.                     | D5071-17-001                                                      | Batch Size         | 174.96kg                                            |
| Batch Type                    | Commercial                                                        | Report Date        | 2017-3-6                                            |
| Retest Date                   | 2019-12                                                           | Storage Condition  | Preserved in a well-closed container                |
| Manufacture Date              | 2017-1-17                                                         | Manufacturing Site | Chuannan, Duqiao, Linhai, Zhejiang<br>317016, China |
| Reference                     | CEP(R0-CEP 2013-189-Rev 01)                                       |                    |                                                     |
| Test Items                    | Specifications                                                    | Results            |                                                     |
| Appearance                    | White or off-white powder                                         | Off-white powder   |                                                     |
| Identification                | (1) IR: IR spectrum is accordant with Tadalafil RS.               | Conform            |                                                     |
|                               | (2) Specific optical rotation: +78.0° to +84.0° (dried substance) | +78.7°             |                                                     |
| Loss on drying                | ≤ 0.5%                                                            | <0.1%              |                                                     |
| Sulfated ash                  | ≤ 0.1%                                                            | <0.1%              |                                                     |
| Assay (HPLC)                  | 97.5%~102.0% (dried substance)                                    | 99.5%              |                                                     |
| *Impurities A, B and C (HPLC) | Impurity A≤ 0.15%                                                 | N.D                |                                                     |
|                               | Unspecified impurities≤ 0.10%                                     | N.D                |                                                     |
| Related substances (HPLC)     | Unspecified impurities≤ 0.10%                                     | 0.05%              |                                                     |
|                               | Total impurities≤ 0.3%                                            | 0.05%              |                                                     |
| Residual Solvents Test 1 (GC) | Methanol≤ 3000 ppm                                                | 86ppm              |                                                     |
| **Genotoxic impurity (GC-MS)  | Methyl chloroacetate≤37.5ppm                                      | N.D                |                                                     |
| Conclusion                    | Complies with CEP(R0-CEP 2013-189-Rev 01)                         |                    |                                                     |

\* Impurity A: (6R,12aS)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]-pyrido[3,4-b]indole-1,4-dione;  
\* Impurity B: (6S,12aS)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]-pyrido[3,4-b]indole-1,4-dione;  
\* Impurity C: (6S,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]-pyrido[3,4-b]indole-1,4-dione  
\*\*Genotoxic impurity: performed for the first three batches.

Signature: Hangxiang (QC manager)

Issued Date: 2017.03.08

Signature: Qijiang (QA manager)

Issued Date: 2017.03.08

Q/ZHH QC-075-1